Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 6/20 | 0.61 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.49 |
| ▸ | JAK3 | P52333 | 2/20 | 0.48 |
| ▸ | LRRK2 | Q5S007 | 6/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.43 |
| ▸ | CDC42BPB | Q9Y5S2 | 1/20 | 0.43 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.41 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.41 |
| ▸ | TPX2 | Q9ULW0 | 1/20 | 0.41 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21024073 | 0.88 | MAPK1 (0.60) | MAPK1CREBBPJAK3LRRK2ROCK2 | |
| SCHEMBL19657316 | 0.83 | MAPK1 (0.67) | MAPK1CREBBPJAK3LRRK2ROCK2 | |
| SCHEMBL19657749 | 0.81 | MAPK1 (0.64) | MAPK1CREBBPJAK3LRRK2ROCK2 | |
| SCHEMBL1849841 | 0.77 | MAPK1 (0.80) | MAPK1CREBBPJAK3ALK | |
| SCHEMBL15652768 | 0.76 | MAPK1 (1.00) | MAPK1CREBBPJAK3 | |
| SCHEMBL31060275 | 0.75 | MAPK1 (0.60) | MAPK1CREBBPJAK3LRRK2ROCK2 | |
| SCHEMBL1848809 | 0.75 | MAPK1 (0.60) | MAPK1CREBBPJAK3LRRK2ROCK2 | |
| SCHEMBL10141887 | 0.73 | MAPK1 (0.68) | MAPK1CREBBPJAK3 | |
| SCHEMBL15653387 | 0.72 | MAPK1 (0.75) | MAPK1CREBBPJAK3 | |
| SCHEMBL21592513 | 0.71 | MAPK1 (0.69) | MAPK1CREBBPJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11168070-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2021-11-09 | — | — | US | disclosed |
| US-20200399244-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2020-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200399244-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | EP300, HDAC1, HDAC3 | MAPK1 909/4885CREBBP 7/4885JAK3 2120/4885 |
| US-11168070-B2 | Therapeutic compounds and uses thereof | EP300, HDAC1, HDAC11 | MAPK1 753/4885CREBBP 6/4885JAK3 2121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.